Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population

OBJECTIVE To report the mortality of left ventricular systolic dysfunction (LVD), assessed objectively by echocardiography, and its association with natriuretic peptide hormones in a random sample of 1640 men and women aged 25–74 years from a geographical, urban population. METHODS Left ventricular function was measured by echocardiography in 1640 attendees studied in 1992–3. LVD was defined as a left ventricular ejection fraction (LVEF) ⩽ 30%. Plasma concentrations of N-terminal atrial natriuretic peptide (N-ANP) and brain natriuretic peptide (BNP) were measured by standard radioimmunoassays. Mortality was documented at four years. RESULTS The four year all cause mortality rate in the whole cohort was 4.9% (80 deaths). It was 21% (nine deaths) in those with an LVEF ⩽ 30% and 4% in those whose LVEF was > 30% (p < 0.001). The median (interquartile range) BNP concentration in those who died was 16.9 pg/ml (8.8–27) and 7.8 pg/ml (3.4–13) in survivors (p < 0.0001). Similarly, N-ANP had a median concentration of 2.35 ng/ml (1.32–3.36) in those with a fatal outcome and 1.27 ng/ml (0.9–2.0) in those alive at four years (p < 0.0001). Subjects with an LVEF ⩽ 40% also had a significant mortality rate of 17% if they also had a BNP concentration ⩾ 17.9 pg/ml compared with 6.8% if their BNP was below this concentration (p = 0.013). Multivariate analysis revealed the independent predictors of four year all cause mortality to be increasing age (p < 0.001), a BNP concentration ⩾ 17.9 pg/ml (p = 0.006), the presence of ischaemic heart disease (p = 0.03), and male sex (p = 0.04). CONCLUSIONS LVD is associated with a considerable mortality rate in this population. BNP also independently predicts outcome. In addition to its role as a diagnostic aid in chronic heart failure and LVD, it provides prognostic information and clarifies the meaning of a given degree of LVD.

[1]  K. Bailey,et al.  Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. , 1998, Circulation.

[2]  C. Frampton,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.

[3]  H. Tunstall-Pedoe,et al.  Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.

[4]  K. Bailey,et al.  Congestive Heart Failure in the Community , 1998 .

[5]  Hugh Tunstall-Pedoe,et al.  Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population , 1997, The Lancet.

[6]  J. Heikkilä,et al.  Associations between atrial natriuretic peptides, echocardiographic findings and mortality in an elderly population sample , 1997, Journal of internal medicine.

[7]  K. Nakao,et al.  Brain natriuretic peptide predicts mortality in the elderly. , 1997, Heart.

[8]  M. Komajda,et al.  Prognostic value of plasma endothelin-1 in patients with chronic heart failure. , 1997, European heart journal.

[9]  N. Bishopric,et al.  Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. , 1996, The Journal of biological chemistry.

[10]  R. T. Lie,et al.  Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. , 1996, Circulation.

[11]  T. MacDonald,et al.  Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure. , 1996, Circulation.

[12]  G. Maurer,et al.  Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. , 1996, Journal of the American College of Cardiology.

[13]  G. Lamas,et al.  N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. , 1994, Circulation.

[14]  K. Bailey,et al.  The incidence and prevalence of congestive heart failure in Rochester, Minnesota. , 1993, Mayo Clinic proceedings.

[15]  W. Edwards,et al.  Natriuretic peptide system in human heart failure. , 1993, Circulation.

[16]  C. Lang,et al.  The effect of intravenous saline loading on plasma levels of brain natriuretic peptide in man , 1993, Journal of hypertension.

[17]  D. Levy,et al.  Survival After the Onset of Congestive Heart Failure in Framingham Heart Study Subjects , 1993, Circulation.

[18]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[19]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[20]  P E Leaverton,et al.  Prevalence and mortality rate of congestive heart failure in the United States. , 1992, Journal of the American College of Cardiology.

[21]  M. Pfeffer,et al.  The effect of treatment on survival in congestive heart failure , 1992, Clinical cardiology.

[22]  T. Horio,et al.  Brain natriuretic peptide as a cardiac hormone in essential hypertension. , 1992, The American journal of medicine.

[23]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[24]  L Wilhelmsen,et al.  Risk factors for heart failure in the general population: the study of men born in 1913. , 1989, European heart journal.

[25]  Ronald J. Prineas,et al.  The Minnesota code manual of electrocardiographic findings : standards and procedures for measurement and classification , 1982 .

[26]  W. Kannel,et al.  The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.